Business Standard

HC quashes Centre's notification to ban FDC drugs

IANS  |  New Delhi 

The High on Thursday quashed the Centre's notification to ban 344 fixed dose combination (FDC) medicines.

The brands included D'Cold Total, Corex cough syrup, and Vicks Action 500, among others.

Justice R.S. Endlaw, allowing the 454 pleas filed by the pharma companies, quashed the Centre's notification issued on March 10.

Companies like Pfizer, Glenmark, Procter and Gamble, Reckitt Benckiser, Cipla and others had moved the against the government decision. The had granted stay on the notification.

The government had told the that medicines sold by pharma majors "endanger patient safety".

It had banned the drugs on the ground that they involve risk to humans and hence needed to be withdrawn immediately and contended that safer alternatives were available.

The pharma companies had argued that the ban order was passed without considering clinical data and had termed the government's claim as absurd.

--IANS

gt/in/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

HC quashes Centre's notification to ban FDC drugs

The Delhi High Court on Thursday quashed the Centre's notification to ban 344 fixed dose combination (FDC) medicines.

The High on Thursday quashed the Centre's notification to ban 344 fixed dose combination (FDC) medicines.

The brands included D'Cold Total, Corex cough syrup, and Vicks Action 500, among others.

Justice R.S. Endlaw, allowing the 454 pleas filed by the pharma companies, quashed the Centre's notification issued on March 10.

Companies like Pfizer, Glenmark, Procter and Gamble, Reckitt Benckiser, Cipla and others had moved the against the government decision. The had granted stay on the notification.

The government had told the that medicines sold by pharma majors "endanger patient safety".

It had banned the drugs on the ground that they involve risk to humans and hence needed to be withdrawn immediately and contended that safer alternatives were available.

The pharma companies had argued that the ban order was passed without considering clinical data and had termed the government's claim as absurd.

--IANS

gt/in/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

HC quashes Centre's notification to ban FDC drugs

The High on Thursday quashed the Centre's notification to ban 344 fixed dose combination (FDC) medicines.

The brands included D'Cold Total, Corex cough syrup, and Vicks Action 500, among others.

Justice R.S. Endlaw, allowing the 454 pleas filed by the pharma companies, quashed the Centre's notification issued on March 10.

Companies like Pfizer, Glenmark, Procter and Gamble, Reckitt Benckiser, Cipla and others had moved the against the government decision. The had granted stay on the notification.

The government had told the that medicines sold by pharma majors "endanger patient safety".

It had banned the drugs on the ground that they involve risk to humans and hence needed to be withdrawn immediately and contended that safer alternatives were available.

The pharma companies had argued that the ban order was passed without considering clinical data and had termed the government's claim as absurd.

--IANS

gt/in/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard